N/A N=176 CareLink® Network Evaluation
Heart Failure
Primary: Comparison of Remote Device Check and In-clinic Device Assessment — 40.0; 50.0; 10.0; 0.0 percentage of Investigators
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)
ARDS
Primary: Number of Participants That Did Not Require Endotrachael Intubation — 3 participants
Phase 3 N=392 Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Acute Coronary Syndrome · Myocardial Infarction · Smoking
Primary: Smoking Abstinence — 32.0; 37.2 percentage of participants
Phase 3 N=811 Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Month 6 Endpoint — -0.57; -0.56 percentage of hemoglobin
Phase 4 N=810 CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)
Tachycardia, Atrioventricular Nodal Reentry
Primary: Device or Procedure Related AV Block Persistent Through Discharge From Hospital. — 0; 0 participants
Phase 3 N=11 Ranolazine and Pulmonary Hypertension
Angina · Pulmonary Arterial Hypertension
Primary: Improve Angina Symptoms — 1.75 units on a scale — p=0.0013
Phase 2 N=14 Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Progression-Free Survival (PFS). — 370 Days
Phase 3 N=807 Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Month 6 Endpoint — -0.83; -0.83 percentage of hemoglobin
Phase 3 N=682 Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)
In Vitro Fertilization
Primary: Percentage of Participants With Clinically Relevant Immunogenicity — 0.0; 0.0; 0.0 percentage of participants
Phase 3 N=878 Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Month 6 Endpoint — -1.42; -1.46 percentage of hemoglobin
Phase 1 N=21 Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
Solid Tumor · Advanced Cancer
Primary: Dose Limiting Toxicity Assessment and Maximum Tolerated Dose Determination — 0.0; 0.0; 50.0; 0.0 percentage of participants
Phase 3 N=365 Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Diabetes Type 2
Primary: Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 — -1.13; -0.75; -0.40 percentage of total hemoglobin — p=0.0010
Phase 3 N=301 Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
Painful Diabetic Peripheral Neuropathy
Primary: Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)…
Phase 3 N=549 Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Change In HbA1c From Baseline to Month 6 Endpoint — -0.40; -0.44 percentage of hemoglobin
Phase 2 N=525 Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Meningococcal Meningitis · Meningococcal Infections
Primary: Seroresponse (Percent Seroconversion). — 70.7; 70.1; 66.5; 72.5 percentage of per protocol participants